➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Harvard Business School
Colorcon
AstraZeneca
Baxter

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Patent: 9,931,309

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,931,309
Title:Curcumin-sophorolipid complex
Abstract: The present invention relates to a complex comprising acidic sophorolipid and curcumin ((SL(A)+Cur), wherein, curcumin is solubilized and nano-encapsulated in acidic sophorolipid to improve the water solubility, stability and bioavailability of curcumin in order to enhance its therapeutic activity. Further, the invention provides pharmaceutical compositions comprising the present complex and methods to treat cancer in a subject using the said composition.
Inventor(s): Singh; Pradeep Kumar (Pune, IN), Prabhune; Asmita Ashutosh (Pune, IN), Ogale; Satishchandra Balkrishna (Pune, IN)
Assignee: Council of Scientific & Industrial Research (New Delhi, IN)
Application Number:15/328,304
Patent Claims:see list of patent claims

Details for Patent 9,931,309

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Council of Scientific & Industrial Research (New Delhi, IN) 2034-07-23 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Council of Scientific & Industrial Research (New Delhi, IN) 2034-07-23 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Council of Scientific & Industrial Research (New Delhi, IN) 2034-07-23 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Council of Scientific & Industrial Research (New Delhi, IN) 2034-07-23 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Council of Scientific & Industrial Research (New Delhi, IN) 2034-07-23 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Council of Scientific & Industrial Research (New Delhi, IN) 2034-07-23 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Council of Scientific & Industrial Research (New Delhi, IN) 2034-07-23 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Harvard Business School
Express Scripts
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.